SCHEMBL25580975

SCHEMBL25580975

c1ccc(-c2ccccc2-c2c(-c3ccccc3)cccc2-c2cccc(N(c3ccccc3)c3ccc4oc5ccccc5c4c3)c2)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 3/20 0.37
▸ HPGD P15428 2/20 0.37
▸ RAB9A P51151 2/20 0.37
▸ SMN1; SMN2 Q16637 2/20 0.37
▸ MAPT P10636 2/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ ALOX5 P09917 2/20 0.36
▸ AHR P35869 2/20 0.34
▸ LMNA P02545 1/20 0.33
▸ HSP90AA1 P07900 1/20 0.32
▸ HSP90AB1 P08238 1/20 0.32
▸ PLA2G2A P14555 2/20 0.32
▸ PLA2G4A P47712 2/20 0.32
▸ PLA2G10 O15496 1/20 0.32
▸ CYP1A2 P05177 1/20 0.32
▸ CYP2D6 P10635 1/20 0.32
▸ CYP2C19 P33261 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25580812 0.98 ALOX5 (0.37) NPC1HPGDRAB9ASMN1; SMN2MAPT
SCHEMBL25580910 0.98 ALOX5 (0.37) NPC1HPGDRAB9ASMN1; SMN2MAPT
SCHEMBL25580698 0.96 NPC1 (0.38) NPC1HPGDRAB9ASMN1; SMN2MAPT
SCHEMBL25580623 0.94 NPC1 (0.38) NPC1HPGDRAB9ASMN1; SMN2MAPT
SCHEMBL25580506 0.94 NPC1 (0.38) NPC1HPGDRAB9ASMN1; SMN2MAPT
SCHEMBL25581035 0.93 ALOX5 (0.47) NPC1HPGDRAB9ASMN1; SMN2MAPT
SCHEMBL25580475 0.93 MCL1 (0.37) NPC1HPGDRAB9ASMN1; SMN2MAPT
SCHEMBL25581002 0.93 MCL1 (0.37) NPC1HPGDRAB9ASMN1; SMN2MAPT
SCHEMBL25580787 0.93 MCL1 (0.36) NPC1HPGDRAB9ASMN1; SMN2MAPT
SCHEMBL25580978 0.93 AHR (0.37) NPC1HPGDRAB9ASMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230180597-A1 COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENTS, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE IDEMITSU KOSAN CO.,LTD. (JP) 2023-06-08 — — US disclosed
US-20230180597-A1 COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENTS, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE IDEMITSU KOSAN CO.,LTD. (JP) 2023-06-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230180597-A1 COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENTS, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE ESR1, L1CAM, ESR2 NPC1 2605/4885HPGD 4709/4885RAB9A 634/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback